Reproductive epidemiology

Discussing Emulating target trials for interventions during pregnancy

PhD thesis public defence - Threatened abortion and long-term health of born children and women

I have officially completed my PhD journey with a public thesis defence, which took place last Friday, 27 January 2023 at the Department of Clinical Epidemiology, Aarhus University. If you’re interested in learning more about my PhD work, you can find a description here: https://lnkd.

Risk of diabetes and cardiovascular diseases in women with pregnancies complicated by vaginal bleeding - Danish population-based cohort study

Women's mortality following a childbirth affected by vaginal bleeding

Women's mortality following a childbirth affected by vaginal bleeding

Vaginal bleeding in pregnancy and women's risk of diabetes and cardiovascular diseases

Postpartum Hemorrhage As a Marker of Cancer

Abstract The association between carcinogenesis and subsequent bleeding is established. We investigated whether postpartum hemorrhage (PPH) may be a marker of clinically unrecognized cancer in women of reproductive age. In the full population, 51 224 women comprised the PPH cohort, and 536 016 women comprised the comparison cohort.

Threatened abortion and risk of epilepsy, cerebral palsy and attention-deficit/hyperactivity disorder (ADHD) in children

Abstract Previous research revealed that children born from threatened abortion (TAB)-affected gestation are at 2-3 fold increased risk of autism spectrum disorders and developmental coordination disorder. In conventional cohort analysis, TAB-affected children had a 21-25% higher relative risk of epilepsy, attention-deficit/hyperactivity disorder (ADHD), in the first 16 years of life and 42% higher relative risk of cerebral palsy in the first 6 years of life.

Hypertensive disorders of pregnancy and utilization of antihypertensive therapies

Background Hypertensive disorders of pregnancy are associated with mortality and morbidity in offspring and mothers. Use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) is contra indicated in pregnancy.

Hypertensive Disorders Of Pregnancy And Utilization Of Antihypertensive Therapies

LACEi or ARBs were dispensed in pregnancies with chronic hypertension (590/735, 80.3%), preeclampsia superimposed on chronic hypertension (130/735, 17.7%), and gestational hypertension (15/735, 2.0%). The utilization of ACEi or ARBs for therapy of HDP was low, but not absent.